These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2116 related articles for article (PubMed ID: 28052254)

  • 21. Checkpoint blocking antibodies in cancer immunotherapy.
    Kyi C; Postow MA
    FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.
    Dong ZY; Wu SP; Liao RQ; Huang SM; Wu YL
    Tumour Biol; 2016 Apr; 37(4):4251-61. PubMed ID: 26779629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Suppression of tumor antigen-specific T cell immune responses by regulatory T cells].
    Shimazu Y; Nishikawa H
    Gan To Kagaku Ryoho; 2014 Sep; 41(9):1057-61. PubMed ID: 25248887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune checkpoint blockade therapy: the 2014 Tang Prize in Biopharmaceutical Science.
    Chen YS; Shen CR
    Biomed J; 2015; 38(1):5-8. PubMed ID: 25673064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
    Harter PN; Bernatz S; Scholz A; Zeiner PS; Zinke J; Kiyose M; Blasel S; Beschorner R; Senft C; Bender B; Ronellenfitsch MW; Wikman H; Glatzel M; Meinhardt M; Juratli TA; Steinbach JP; Plate KH; Wischhusen J; Weide B; Mittelbronn M
    Oncotarget; 2015 Dec; 6(38):40836-49. PubMed ID: 26517811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reversing T-cell Dysfunction and Exhaustion in Cancer.
    Zarour HM
    Clin Cancer Res; 2016 Apr; 22(8):1856-64. PubMed ID: 27084739
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interferon-γ Production by Peripheral Lymphocytes Predicts Survival of Tumor-Bearing Mice Receiving Dual PD-1/CTLA-4 Blockade.
    McNamara MJ; Hilgart-Martiszus I; Barragan Echenique DM; Linch SN; Kasiewicz MJ; Redmond WL
    Cancer Immunol Res; 2016 Aug; 4(8):650-7. PubMed ID: 27262113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune checkpoint inhibitors for cancer treatment.
    Park J; Kwon M; Shin EC
    Arch Pharm Res; 2016 Nov; 39(11):1577-1587. PubMed ID: 27770382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
    Meng X; Huang Z; Teng F; Xing L; Yu J
    Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy.
    Angelova M; Charoentong P; Hackl H; Fischer ML; Snajder R; Krogsdam AM; Waldner MJ; Bindea G; Mlecnik B; Galon J; Trajanoski Z
    Genome Biol; 2015 Mar; 16(1):64. PubMed ID: 25853550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune Checkpoint Inhibitors.
    Haanen JB; Robert C
    Prog Tumor Res; 2015; 42():55-66. PubMed ID: 26382943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy for advanced melanoma: Current knowledge and future directions.
    Nakamura K; Okuyama R
    J Dermatol Sci; 2016 Aug; 83(2):87-94. PubMed ID: 27302423
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen.
    Sharabi AB; Nirschl CJ; Kochel CM; Nirschl TR; Francica BJ; Velarde E; Deweese TL; Drake CG
    Cancer Immunol Res; 2015 Apr; 3(4):345-55. PubMed ID: 25527358
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma.
    Wang SD; Li HY; Li BH; Xie T; Zhu T; Sun LL; Ren HY; Ye ZM
    Int Immunopharmacol; 2016 Sep; 38():81-9. PubMed ID: 27258185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conflicting consequences of immunity to cancer versus autoimmunity to neurons: insights from paraneoplastic disease.
    Steinman L
    Eur J Immunol; 2014 Nov; 44(11):3201-5. PubMed ID: 25319369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Immune-checkpoints: the new anti-cancer immunotherapies].
    Ileana E; Champiat S; Soria JC
    Bull Cancer; 2013 Jun; 100(6):601-10. PubMed ID: 23735730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer.
    Czink E; Kloor M; Goeppert B; Fröhling S; Uhrig S; Weber TF; Meinel J; Sutter C; Weiss KH; Schirmacher P; Doeberitz MVK; Jäger D; Springfeld C
    Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28619747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors.
    Siemers NO; Holloway JL; Chang H; Chasalow SD; Ross-MacDonald PB; Voliva CF; Szustakowski JD
    PLoS One; 2017; 12(7):e0179726. PubMed ID: 28749946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genomic Characterization of Six Virus-Associated Cancers Identifies Changes in the Tumor Immune Microenvironment and Altered Genetic Programs.
    Varn FS; Schaafsma E; Wang Y; Cheng C
    Cancer Res; 2018 Nov; 78(22):6413-6423. PubMed ID: 30254145
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?
    Gerber HP; Sapra P; Loganzo F; May C
    Biochem Pharmacol; 2016 Feb; 102():1-6. PubMed ID: 26686577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 106.